KLRS — Kalaris Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Kalaris Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -172 | -169 | -190 | -58.8 | -43.4 |
| Depreciation | |||||
| Non-Cash Items | 46.1 | 42.1 | 63.5 | 16.4 | 1.63 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 19.4 | -16.1 | 2.02 | -25.3 | 3.43 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | -106 | -142 | -124 | -67.7 | -38.4 |
| Capital Expenditures | -0.026 | 0 | — | — | -0.2 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 186 | -80.5 | 38 | 95 | -19.5 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 186 | -80.5 | 38 | 95 | -19.7 |
| Financing Cash Flow Items | 0 | — | — | — | 106 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.232 | 127 | 70.5 | 0.021 | 155 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 79.9 | -95.6 | -16 | 27.3 | 96.9 |